92 related articles for article (PubMed ID: 11550502)
1. [Pefloxacin (abactal) efficacy in severe pneumonia].
Aleksanian LA
Antibiot Khimioter; 2001; 46(4):19-21. PubMed ID: 11550502
[No Abstract] [Full Text] [Related]
2. Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.
Tatsis G; Tsoukalas G; Hatzinikolaou V; Boulbasakos G; Jordanoglou J
J Int Med Res; 1996; 24(6):478-81. PubMed ID: 8959532
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of pefoxacin (abactal) in the complex treatment of patients with pancreonecrosis].
Gel'fand BR; Burnevich SZ; Gel'fand EB; Tsydenzhapov ETs; Briukhov AN; Brazhnik TB; Saganov VP; Pukhaev DA
Antibiot Khimioter; 2001; 46(5):24-7. PubMed ID: 11558450
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of pefloxacin in brucellosis].
Kurmanova KB; Kkhamfyang S; Iudin SM
Antibiot Khimioter; 1995 Jul; 40(7):39-42. PubMed ID: 8645059
[TBL] [Abstract][Full Text] [Related]
5. Acute gout in a patient taking pefloxacin--a case report.
Kundu AK
J Indian Med Assoc; 1996 Nov; 94(11):427. PubMed ID: 9141871
[No Abstract] [Full Text] [Related]
6. [Intracranial hypertension in an infant treated with fluoroquinolone in Madagascar].
Ramarovavy G; Imbert P; Razaiarinoro J; Langue J; Rasolofoharinoro B; Gerbay A; Randriambelomanana A
Arch Pediatr; 2005 Oct; 12(10):1527-8. PubMed ID: 16099146
[No Abstract] [Full Text] [Related]
7. Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy.
Leelarasamee A; Leelarasamee I
Drugs; 1995; 49 Suppl 2():365-7. PubMed ID: 8549364
[No Abstract] [Full Text] [Related]
8. [Use of pefloxacin in the treatment of infected burn wounds].
Iakovlev VP; Alekseev AA; Krutikov MG; Grishina IA; Izotova GN
Antibiot Khimioter; 1996 Jun; 41(6):39-43. PubMed ID: 9054328
[TBL] [Abstract][Full Text] [Related]
9. [Pefloxacin (Abactal): role in modern therapy of bacterial infections].
Fomina IP; Smirnova LB
Antibiot Khimioter; 2000; 45(8):42-7. PubMed ID: 10989724
[No Abstract] [Full Text] [Related]
10. [Pefloxacin in the treatment of patients with mucoviscidosis].
Postnikov SS; Semykin SIu; Polikarpova SV; Nazhimov VP
Antibiot Khimioter; 2002; 47(4):13-5. PubMed ID: 12369138
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of pefloxacin in the surgical clinic].
Iakovlev VP; Blatun LA; Khlebnikov EP; Elagina LV; Puchkova LS
Antibiot Khimioter; 1995 Aug; 40(8):43-5. PubMed ID: 8713438
[TBL] [Abstract][Full Text] [Related]
12. [Pefloxacin (Abactal): role in treatment of severe surgical infections].
Gel'fand EB
Antibiot Khimioter; 2000; 45(8):48. PubMed ID: 10989725
[No Abstract] [Full Text] [Related]
13. Hypersensitivity anaphylactoid reaction to pefloxacin in a patient with AIDS.
al-Hedaithy MA; Noreddin AM
Ann Pharmacother; 1996 Jun; 30(6):612-4. PubMed ID: 8792948
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of sequential intravenous-oral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions.
Yap JC; Wang YT; Chan CC; Ng A; Poh SC
Singapore Med J; 1995 Oct; 36(5):484-6. PubMed ID: 8882529
[TBL] [Abstract][Full Text] [Related]
15. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
Postnikov SS
Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pefloxacin in the treatment of postoperative sepsis in gynaecology.
Arowojolu AO; Bakare RA; Oni AA; Ayodele AE; Kayode OO
Afr J Med Med Sci; 1999; 28(3-4):151-3. PubMed ID: 11205820
[TBL] [Abstract][Full Text] [Related]
17. Pefloxacin in the treatment of acute severe infections in hospitalized patients. Clinical and bacteriological evaluation.
Giustina A; Romanelli G; Cravarezza P; Ravizzola G; Turano A
J Chemother; 1989 Jul; 1(4 Suppl):668-9. PubMed ID: 16312584
[No Abstract] [Full Text] [Related]
18. [Pefloxacin (Abaktal)--efficacy in treating severe infections, optimization of treatment based on pharmacokinetic and pharmacodynamic parameters].
Budanov SV; Vasil'ev AN; Smirnov LB
Antibiot Khimioter; 2002; 47(12):31-6. PubMed ID: 12728632
[No Abstract] [Full Text] [Related]
19. [Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases].
Navashin PS; Smirnova LB
Antibiot Khimioter; 1998; 43(12):30-8. PubMed ID: 10079873
[No Abstract] [Full Text] [Related]
20. [Exacerbation of myasthenia gravis by pefloxacin].
Vial T; Chauplannaz G; Brunel P; Leriche B; Evreux JC
Rev Neurol (Paris); 1995 Apr; 151(4):286-7. PubMed ID: 7481384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
